Name: UMIN ID:
Unique ID issued by UMIN | UMIN000001127 |
---|---|
Receipt number | R000001374 |
Scientific Title | Phase II study of Bevacizumab plus modified OPTIMOX1 in patients with unresectable advanced/recurrent colorectal cancer |
Date of disclosure of the study information | 2008/06/01 |
Last modified on | 2015/07/09 15:05:28 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2008/04/23 15:14:53 | ||
2 | Update | 2008/07/23 11:46:44 | Recruitment status Date of protocol fixation |
|
3 | Update | 2008/09/24 10:48:21 | Key inclusion criteria |
|
4 | Update | 2008/09/24 11:01:35 | Organization Organization Division name Division name Address Address |
|
5 | Update | 2009/04/27 10:06:37 | Public title |
|
6 | Update | 2009/04/27 10:08:44 | Narrative objectives1 Narrative objectives1 |
|
7 | Update | 2009/04/27 10:09:02 | Public title |
|
8 | Update | 2009/08/25 16:54:45 | Last follow-up date |
|
9 | Update | 2009/11/17 10:54:13 | Recruitment status |
|
10 | Update | 2010/04/22 11:30:14 | Last follow-up date |
|
11 | Update | 2010/08/26 15:20:48 | Acronym Acronym |
|
12 | Update | 2010/10/25 09:48:49 | Name of person sending information Address |
|
13 | Update | 2010/10/25 09:49:11 | Recruitment status |
|
14 | Update | 2011/10/25 10:10:13 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
15 | Update | 2011/11/10 11:56:34 | Address Address Address Address1 |
|
16 | Update | 2012/09/13 09:19:27 | Publication of results URL related to results and publications |
|
17 | Update | 2015/02/04 09:36:28 | Organization Organization Division name Division name Address Address TEL Last name of contact person Last name of contact person Address TEL Name of person sending information Name of person sending information Division name Division name Email1 |
|
18 | Update | 2015/06/30 11:14:52 | Recruitment status Publication of results URL related to results and publications |
|
19 | Update | 2015/07/09 15:05:28 | URL related to results and publications |